Production (Stage)
GenSight Biologics S.A.
GSGTF
$0.24
-$0.08-25.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.62M | 1.25M | 868.70K | 1.13M | 1.37M |
| Total Other Revenue | 1.22M | 1.24M | 1.27M | 1.56M | 1.83M |
| Total Revenue | 2.84M | 2.49M | 2.14M | 2.68M | 3.20M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 2.84M | 2.49M | 2.14M | 2.68M | 3.20M |
| SG&A Expenses | 6.57M | 7.80M | 9.01M | 11.73M | 14.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.95M | 21.90M | 23.78M | 29.65M | 35.31M |
| Operating Income | -17.11M | -19.41M | -21.64M | -26.96M | -32.11M |
| Income Before Tax | -15.13M | -18.46M | -21.75M | -25.12M | -28.36M |
| Income Tax Expenses | 22.70K | 13.10K | 3.20K | 1.60K | 0.00 |
| Earnings from Continuing Operations | -15.15 | -18.48 | -21.76 | -25.12 | -28.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.15M | -18.48M | -21.76M | -25.12M | -28.36M |
| EBIT | -17.11M | -19.41M | -21.64M | -26.96M | -32.11M |
| EBITDA | -16.94M | -18.47M | -19.93M | -24.93M | -29.75M |
| EPS Basic | -0.16 | -0.27 | -0.38 | -0.48 | -0.59 |
| Normalized Basic EPS | -0.10 | -0.17 | -0.24 | -0.30 | -0.37 |
| EPS Diluted | -0.16 | -0.27 | -0.38 | -0.48 | -0.59 |
| Normalized Diluted EPS | -0.10 | -0.17 | -0.24 | -0.30 | -0.37 |
| Average Basic Shares Outstanding | 383.02M | 324.82M | 266.62M | 230.02M | 193.35M |
| Average Diluted Shares Outstanding | 383.02M | 324.82M | 266.62M | 230.02M | 193.35M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |